Ceftobiprole is a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus. It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development. Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-re...
For the treatment of serious bacterial infections in hospitalised patients.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.